The Clinton Health Access Initiative, Inc. (CHAI) is a global health organization committed to our mission of saving lives and reducing the burden of disease in low-and middle-income countries. We work at the invitation of governments to support them and the private sector to create and sustain high-quality health systems.
CHAI was founded in 2002 in response to the HIV/AIDS epidemic with the goal of dramatically reducing the price of life-saving drugs and increasing access to these medicines in the countries with the highest burden of the disease. Over the following two decades, CHAI has expanded its focus. Today, along with HIV, we work in conjunction with our partners to prevent and treat infectious diseases such as COVID-19, malaria, tuberculosis, and hepatitis. Our work has also expanded into cancer, diabetes, hypertension, and other non-communicable diseases, and we work to accelerate the rollout of lifesaving vaccines, reduce maternal and child mortality, combat chronic malnutrition, and increase access to assistive technology. We are investing in horizontal approaches to strengthen health systems through programs in human resources for health, digital health, and health financing. With each new and innovative program, our strategy is grounded in maximizing sustainable impact at scale, ensuring that governments lead the solutions, that programs are designed to scale nationally, and learnings are shared globally.
At CHAI, our people are our greatest asset, and none of this work would be possible without their talent, time, dedication and passion for our mission and values. We are a highly diverse team of enthusiastic individuals across 40 countries with a broad range of skillsets and life experiences. CHAI is deeply grounded in the countries we work in, with majority of our staff based in program countries.
In India, CHAI works in partnership with its India registered affiliate William J Clinton Foundation (WJCF) under the guidance of the Ministry of Health and Family Welfare (MoHFW) at the Central and States’ levels on an array of high priority initiatives aimed at improving health outcomes. Currently, WJCF supports government partners across projects to expand access to quality care and treatment for HIV/AIDS, Hepatitis, tuberculosis, COVID-19, common cancers, sexual and reproductive health, immunization, and essential medicines.
Learn more about our exciting work: http://www.clintonhealthaccess.org
Program Overview
Type 1 Diabetes Mellitus (T1D) is an auto-immune disease characterized by reduced ability to produce insulin in the body. T1D usually develops in children, adolescents, or young adults, leading to a lifetime dependence on insulin for survival. The condition is associated with a significant strain and poor quality of life, and leading to a high financial burden, for people living with Type 1 Diabetes (PLT1D) and their families. However, with access to timely diagnostic, initiation on treatment and proper management of the condition, people living with T1D can lead healthy and productive lives, while achieving life expectancy comparable to the general population.
There are an estimated 9.4 million PLT1D globally, with India having the second highest share accounting for 8%-10% of the global prevalence. However, nearly 18% of children and adolescents with T1D (~0.3 million) live in India, the highest in the world. The incidence of T1D in the 0-19 age group is increasing more than any other age group. The estimated global incidence of T1D in 0-19 age group was 8.15 per 100,000 in 2024 and is estimated to increase to 13.95 per 100,000 by 2040.
While the burden of T1D has continued to rise over the years, survival has remained poor. Survival rates for children and adolescents with T1D in India is worse compared to countries with similar socio-economic development. On average, a child diagnosed with T1D at the age of 10 years lives only an additional 29 years of healthy life, contributing to premature mortality and loss of productivity.
There is an urgent need to strengthen access to services and care for Type 1 Diabetes. WJCF’s Type 1 Diabetes program aims at strengthening and improving access to quality T1D care in India, with the overall goal of achieving longer, healthier, and more productive lives for People Living with Type 1 Diabetes (PLT1D). The program aims to address critical barriers to access and delivery of quality T1D care in India by building awareness, improving access to detection, diagnosis, treatment, and follow-up services and care, enabling treatment adherence and self-management, and strengthening governance and policy framework for delivery of T1D care.
Position summary
WJCF seeks a highly motivated and entrepreneurial individual with demonstrated analytical and stakeholder management abilities for the role of Analyst, Type 1 Diabetes (Chhattisgarh). The Analyst will actively engage and support program implementation work, by developing a comprehensive understanding of the public health system and barriers in access to care for Type 1 Diabetes. The Analyst will support program implementation at the state level, including support in roll-out of key interventions to strengthen care for Type 1 Diabetes that involves analytical support; coordinating field-level activities, including monitoring, evaluation and reporting on progress; extensive stakeholder engagement; and understanding and identifying key risks mitigation mechanisms.
The ideal candidate should have exceptional interpersonal skills, be able to work independently, be flexible, be comfortable working and coordinating operations across cross-functional teams and have a strong commitment to excellence. This Analyst role is a high impact role for young professionals determined to positively impact public health outcomes and allows for rich stakeholder engagement.
#jobreference1 #region2